Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

November 8, 2022

https://www.globenewswire.com/news-release/2022/11/08/2550675/0/en/Foghorn-Therapeutics-Provides-Third-Quarter-2022-Financial-and-Corporate-Update.html

– FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023

– FHD-609 Phase 1 pharmacodynamic data shows degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies; initial Phase 1 dose escalation efficacy and safety data expected in 2023

Read more at globenewswire.com

Related news for (FHTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.